Novo Nordisk Announces Headline Results From The FRONTIER 2 Trial; Achieved Its Co-Primary Endpoints By Demonstrating A Reduction Of Treated Bleeding Episodes With Both Once-Weekly And Once-Monthly Mim8 Versus No Prophylaxis Treatment And Prior...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.